LPCN Lipocine Inc.

1.72
+0.03  (+2%)
Previous Close 1.69
Open 1.7
Price To Book 3.13
Market Cap 36969645
Shares 21,464,030
Volume 51,554
Short Ratio
Av. Daily Volume 727,911

SEC filingsSee all SEC filings

  1. 8-K - Current report 19600629
  2. 8-K - Current report 19543858
  3. 8-K - Current report 19538640
  4. 8-K - Current report 19534305
  5. 8-K - Current report 19530049

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b top-line data released September 2016. End of Phase 2b meeting with FDA planned 1Q 2018.
LPCN 1111
Oral testosterone product
CRL issued June 2016. Further CRL issued May 9, 2018. Data from ambulatory blood pressure trial due 1Q 2019.
LPCN 1021
Men with low testosterone (Low T)
Conduct food/fact effect study 2H 2018 in preparation for Phase 3 trial.
LPCN 1107
Prevention of preterm birth ("PTB").
8-week data released January 17, 2019 with 16-week data due later in 1Q 2019.
LPCN 1144
Non-alcoholic fatty liver disease (NAFLD) / Non-alcoholic steatohepatitis (NASH)

Latest News

  1. Lipocine Inc. Announces FDA Clearance of IND to Commence Phase 2 Study of LPCN 1144 in Biopsy Confirmed NASH Subjects
  2. LPCN: Soldiering on and Winning Some Battles
  3. 4 Healthcare Stocks Looking To Have A Strong Thursday (1/24/19)
  4. Lipocine Files IND To Evaluate LPCN 1144 In Biopsy Confirmed NASH Subjects
  5. Lipocine's NASH Candidate Shows Promise In Liver Fat Study
  6. Lipocine's stock rockets on premarket leading volume after upbeat liver fat study results
  7. Lipocine's NASH Therapy Candidate Achieves Meaningful Liver Fat Reduction Based on Interim Results
  8. USPTO Grants Priority Motion To Lipocine And Enters Judgment Against Clarus
  9. Lipocine Announces Successful Ex Vivo Conversion Assessment of TLANDO™
  10. Lipocine Announces LPCN 1144 Clinical Trial Results Selected for Presentation at 2019 NASH-TAG Conference
  11. Lipocine Announces LPCN 1144 MRI-PDFF Clinical Results Selected for Presentation at Keystone Symposia on Integrated Pathways of Disease in NASH and NAFLD
  12. LPCN: Tlando Readouts Coming Soon; NDA to Follow
  13. Lipocine Inc (NASDAQ:LPCN): Are Analysts Optimistic?
  14. Lipocine: 3Q Earnings Snapshot
  15. Lipocine Announces Financial and Operational Results for the Three and Nine Months Ended September 30, 2018
  16. Lipocine Announces Completion of Enrollment in LPCN 1144 Liver Imaging Study in Subjects At-Risk for NASH
  17. Lipocine Announces Completion of Enrollment in Ambulatory Blood Pressure Study for TLANDO™
  18. LPCN: Androgen Therapy in NASH: A Comprehensive Approach
  19. Lipocine Announces LPCN 1144 Clinical Trial Results Selected for Late-Breaker Presentation at The Liver Meeting® 2018

SEC Filings

  1. 8-K - Current report 19600629
  2. 8-K - Current report 19543858
  3. 8-K - Current report 19538640
  4. 8-K - Current report 19534305
  5. 8-K - Current report 19530049
  6. 8-K - Current report 19523669
  7. 8-K - Current report 19512211
  8. 8-K - Current report 181258647
  9. 8-K - Current report 181247596
  10. 8-K - Current report 181244667